Across TCGA pan-cancer cohorts, CHML Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CHML data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CHML Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHML expression acts as an unfavorable survival marker.
OV, BRCA, and LUSC are the cancer types where CHML Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.